Filing Flows › Ensysce Biosciences (ENSC) › Q2 2025
Ensysce Biosciences (ENSC) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 13, 2025
Ensysce Biosciences (ENSC) reported revenue of $1.4M for the second quarter 2025 (Q2 2025), +654% from a year earlier and +4% from the quarter before. Operating margin was -127.6%, net loss $1.7M (126.4% of revenue).
Ensysce Biosciences, Q2 2025: revenue $1.4M (+654% year over year), operating margin -127.6%, net loss $1.7M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | +4% | +654% |
| Operating profit | −$1.8M | — | — |
| Net earnings | −$1.7M | — | — |
| Operating cash flow | −$2.7M | — | — |
What changed
Revenue was $1.4M in Q2 2025, up 654% year over year and up 4% from the previous quarter.
Operating costs exceeded revenue by $1.8M, an operating margin of -127.6%. Total costs grew 46% against revenue growth of 654%. The fastest-growing cost line was Research & development (+103%). The quarter ended with a net loss of $1.7M, narrower than the previous quarter's $1.9M loss.
Operating cash flow was −$2.7M. Non-cash charges added back $91K of share-based compensation. Working capital and other items used $1.1M.
Questions
What was Ensysce Biosciences' revenue in the second quarter 2025?
Ensysce Biosciences (ENSC) reported revenue of $1.4M for the second quarter 2025 (Q2 2025), +654% from a year earlier and +4% from the quarter before.
Was Ensysce Biosciences profitable in the second quarter 2025?
Operating loss was $1.8M (-127.6% of revenue) and net loss $1.7M.